scholarly journals Pewarnaan Toluidin blue sebagai petanda ketepatan biopsi pasca terapi karsinoma sel skuamosa kepala-leher

2012 ◽  
Vol 42 (1) ◽  
Author(s):  
Bambang Hariwiyanto ◽  
Camelia Herdini ◽  
Inawati Bobot
Keyword(s):  
Squamous Cell Carcinoma ◽  
Positive Predictive Value ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Negative Predictive Value ◽  
Predictive Value ◽  
Frozen Section ◽  
Post Treatment ◽  
Malignant Cells ◽  
Specificity Test

Background: Squamous cell carcinoma (SCC) is the most frequent malignancy in the head and neck. The treatment modalities of SCC are surgery followed by chemotherapy and/or radiotherapy, could also chemotherapy and/or radiotherapy without surgery. The gold standard of assessing success  in SCC treatment is if there no malignant cells found not only in frozen section tissues, but also in  post chemotherapy and/or radiotherapy tissues. Determining the spot of biopsy tissue for malignancy assessment after treatment is not easy. Toluidin Blue (TB) is a staining material, absorbed by intercellular space in epithelial dysplasia, included SCC.   To determine the validity of Toluidin Blue as sign of accuracy for biopsy site in SCC post treatment malignancy, which not only for surgically treated cases, but also after chemotherapy and/or radiotherapy without surgical treatment. Method: Diagnostic test study to determine sensitivity test, specificity test, positive predictive value and negative predictive value of TB to detect malignant cells in post treatment head and neck SCC patients. Result: There were 30 samples biopsy material from 30 post treatment SCC patients. Sensitivity test was 83,3%, specificity  test: 66,7%, positive predictive value: 79.0%, negative predictive value: 72,7%. Conclusion: TB staining is accurate for determining biopsy spot in post treatment head and neck SCC. Keyword : Validity, toluidin blue, squamous cell carcinoma, post treatment.  Abstrak :  Latar belakang: Karsinoma sel skuamosa (KSS) merupakan jenis keganasan kepala dan leher yang paling sering dijumpai dibanding keganasan yang lain. KSS kepala leher dapat dilakukan terapi pembedahan diikuti kemoterapi dan/atau radioterapi maupun kemoterapi dan/atau radioterapi tanpa pembedahan. Penentuan keberhasilan radikalitas pengobatan ditandai dengan tidak adanya sisa tumor secara mikroskopis yang diambil pada jaringan pasca kemoradiasi tanpa pembedahan, atau pemeriksaan jaringan secara frozen section. Untuk menentukan apakah pada jaringan masih ada sisa tumor atau sudah bebas tumor secara makroskopis terkadang sulit. Toluidin Blue (TB) adalah zat pewarna yang dapat terserap pada ruang interseluler epitel yang mengalami displasia seperti yang terjadi pada KSS. Tujuan: Menilai validitas pewarnaan TB sebagai petanda ketepatan lokasi biopsi KSS pasca terapi, baik pasca pembedahan, maupun yang diterapi dengan kemoterapi dan/atau radioterapi tanpa pembedahan. Metode: Uji diagnostik untuk menentukan sensitifitas dan spesifitas pewarnaan, nilai duga positif dan nilai duga negatif TB sebagai salah satu petanda ketepatan biopsi KSS pasca terapi KSS kepala-leher. Hasil: Didapatkan 30 sampel penelitian yang berasal dari 26 penderita KSS yang telah dilakukan terapi baik bedah maupun kemoradiasi tanpa bedah. Sensitifitas pewarnaan TB terhadap hasil biopsi pasca terapi 83,3%, spesifitas 66,7%, nilai duga positif 79,0% dan nilai duga negatif 72,7%. Kesimpulan: Pewarnaan TB valid untuk menentukan ketepatan biopsi keganasan KSS kepala dan leher pasca terapi. Kata kunci: Validitas, toluidin blue, karsinoma sel skuamosa, pasca terapi

scholarly journals Greater specificity of p40 compared with p63 in distinguishing squamous cell carcinoma from adenocarcinoma in effusion cellblocks

CytoJournal ◽  
2020 ◽  
Vol 17 ◽  
pp. 13
Author(s):  
Nah Ihm Kim ◽  
Ji Shin Lee
Keyword(s):  
Squamous Cell Carcinoma ◽  
Positive Predictive Value ◽  
Cell Carcinoma ◽  
Negative Predictive Value ◽  
Tumor Cells ◽  
Squamous Cell ◽  
Predictive Value ◽  
Immunocytochemical Staining ◽  
Nuclear Staining ◽  
Malignant Effusions

Objective: Squamous cell carcinoma (SCC) rarely causes malignant effusions. Distinguishing between SCC and adenocarcinoma in effusion cytology can be a challenge. p63 and p40 have been frequently used to support squamous cell differentiation in both histological and cytological specimens. However, similar results in cytological preparations of effusion fluids have been rarely reported. This study was designed to assess the diagnostic value of p63 and p40 immunoreactivity for the differentiation of SCC from adenocarcinoma in malignant effusions. Materials and Methods: Immunocytochemical staining of p63 and p40 was performed on thirty cellblock specimens, including ten malignant effusions carrying SCC and twenty malignant effusions showing adenocarcinoma. Any degree of nuclear staining was considered positive. Results: Of the ten SCC cases, 100% tested positive for both p63 and p40, and most cases showed diffuse staining (>25% of tumor cells). The expression of p63 and p40 was detected in 4 (20%) and 2 (10%) of twenty adenocarcinoma cases, and the extent of staining was all focal (≤25% of tumor cells). The p63 reactivity showed 100% sensitivity, 80% specificity, 71% positive predictive value, and 100% negative predictive value for the differentiation of SCC from adenocarcinoma in malignant effusions. The sensitivity of p40 for SCC was 100%, the specificity was 90%, the positive predictive value was 83%, and the negative predictive value was 100%. Conclusion: Although p63 and p40 are both useful markers for the diagnosis of SCC in malignant effusions, p40 is more specific than p63 in distinguishing SCC from adenocarcinoma.

Lymph Node Clustering in Head and Neck Squamous Cell Cancer

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P39-P40 ◽  
Author(s):  
Kimberly J. Lee ◽  
Claudia Kirsch ◽  
James William Sayre ◽  
Sunita Bhuta ◽  
Elliot Abemayor
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Positive Predictive Value ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Predictive Value ◽  
Neck Squamous Cell Carcinoma ◽  
Level Ii ◽  
Node Clustering

Objective Detection of early regional metastasis of head and neck carcinoma is critical for tumor staging, prognosis, and treatment strategies. Clustered cervical lymphadenopathy portends a worse prognosis than isolated lymphadenopathy, but studies analyzing its effect are lacking. Key objectives include: 1) to establish criteria for lymph node clustering and 2) to assess the predictive value of lymph node clustering for metastasis. Methods This study retrospectively reviewed preoperative radiographic images of 29 patients with histopathologically proven metastatic head and neck squamous cell carcinoma between January 2006 and December 2007. Patients who had previous radiation or chemotherapy were excluded. CT, MRI, and PET CT images were assessed for lymph node size and number, neck level, and clustering, with respect to primary tumor location and size. A cluster was defined as 3 or more abutting nodes with no definable intervening fat planes. Results Statistics comparing histopathologic proven metastatic lymphadenopathy and radiographic clustering of nodes in each neck level were used to elucidate the positive predictive value via logistic regression analysis. Analysis revealed a positive predictive value for clustering of nodes greater than 1 cm to be 82.9%, with a negative predictive value of 100% in the level II region (p<0.05). Nodes in the remaining levels demonstrated less predictive values. Conclusions Clustered lymph nodes greater than 1cm in the level II region in head and neck squamous cell carcinoma have a high predictive value, suggesting that clustering is not only an important prognostic indicator but also an important radiographic feature that may assist surgeons in preoperative surgical planning.

scholarly journals Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

2018 ◽  
Vol 39 (10) ◽  
pp. 1884-1888 ◽  
Author(s):  
P. Wangaryattawanich ◽  
B.F. Branstetter ◽  
M. Hughes ◽  
D.A. Clump ◽  
D.E. Heron ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Negative Predictive Value ◽  
Squamous Cell ◽  
Predictive Value ◽  
Fdg Pet ◽  
Neck Squamous Cell Carcinoma ◽  
Pet Ct ◽  
Fdg Pet Ct

Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 6557-6557
Author(s):  
Charles Abbott ◽  
Nikita Bedi ◽  
Simo V Zhang ◽  
Robin Li ◽  
Rachel Pyke ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Solid Tumor ◽  
Liquid Biopsy ◽  
Resistance Mechanisms ◽  
Post Treatment ◽  
Plasma Samples ◽  
Liquid Biopsies

6557 Background: The reduced scope, and number of genes profiled by typical liquid biopsy panels can result in missed biomarkers including neoantigens, which may change with treatment, as well as potentially undetected resistance mechanisms and pathways beyond the scope of targets typically captured by panels. To address these limitations, we used a whole-exome scale liquid biopsy monitoring platform, NeXT Liquid Biopsy, to analyze head and neck squamous cell carcinoma (HNSCC) patients that have received anti-PD1 therapy. Presently, we sought to (1) monitor neoantigen changes in cfDNA as a complement to tumor biopsy-derived neoantigens, (2) compare the impact of tumor escape mechanisms, including HLA-LOH, on neoantigens identified in tissue and cfDNA and (3) to identify novel biological signatures that combine information from both solid tumor and liquid biopsies. Methods: Pre- and post-intervention matched normal, tumor and plasma samples were collected from a cohort of 12 patients with HNSCC. Following baseline sample collection all patients received a single dose of nivolumab, followed by resection approximately one month later when feasible, or a second biopsy where resection was impractical. Solid tumor and matched normal samples were profiled using ImmunoID NeXT, an augmented exome/transcriptome platform and analysis pipeline. Exome-scale somatic variants were identified in cfDNA from plasma samples using the NeXT Liquid Biopsy platform. Data from these two platforms were compared with corresponding clinical findings. Results: Concordant somatic events were detected between plasma and tumor at pre- and post-treatment timepoints. Neoantigens predicted to arise from these somatic events were reduced in solid tumor post-treatment, but increased in cfDNA, when compared to pre-treatment timepoints. HLA LOH was identified in a number of subjects, likely resulting in reduced neoepitope presentation in those cases. Immune cell infiltration increased in the tumor following treatment, with no changes to the CD8+/Treg cell ratio, suggesting consistent immunoregulation. Conclusions: Exome-wide neoantigen burden was reliably predicted from cfDNA, providing additional insight complementing data from solid tumor. Analyzing HLA LOH, and neoantigen burden from both solid and liquid biopsies together over the course of treatment creates a more comprehensive profile of therapeutic response and resistance mechanisms in HNSCC patients missed with typical liquid biopsy panels.

Sign in / Sign up

Export Citation Format

Share Document